Fred Saad, MD, on implications of phase 3 ARANOTE data in mHSPC - Urology Times
Fred Saad discusses the ARANOTE trial findings at the 2024 ESMO Annual Congress, highlighting darolutamide plus ADT's significant reduction in radiological progression or death risk in mHSPC patients. He envisions this becoming a new standard of care, expanding therapeutic options, and plans to explore earlier disease settings and combinations with other drugs.
Related Clinical Trials
Reference News
Fred Saad, MD, on implications of phase 3 ARANOTE data in mHSPC - Urology Times
Fred Saad discusses the ARANOTE trial findings at the 2024 ESMO Annual Congress, highlighting darolutamide plus ADT's significant reduction in radiological progression or death risk in mHSPC patients. He envisions this becoming a new standard of care, expanding therapeutic options, and plans to explore earlier disease settings and combinations with other drugs.